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ABSTRACT
Previous work suggested that interleukin (IL)–2 can be used for eradicating residual disease in autologous
grafts and for preventing recurrence. We report a phase II study of autologous peripheral blood stem cell
transplantation with in vitro IL-2 incubation of peripheral blood stem cells and posttransplantation IL-2 in
patients with recurrent or refractory non-Hodgkin lymphoma. Salvage chemotherapy consisted of ifosfamide
and etoposide. Responding patients underwent autologous peripheral blood stem cell transplantation. IL-2–
incubated stem cells were infused on day 0. IL-2 1 mIU/m2 was given from day 1 until day 28. Four monthly
maintenance cycles of IL-2 4 mIU/m2 subcutaneously twice daily days 1 to 5 and days 8 to 11 were administered
thereafter. Eighty-four evaluable patients were enrolled, and 60 proceeded to transplantation, of which 56
received IL-2–incubated stem cells. The average received dose of posttransplantation IL-2 was 30% to 50% of
planned. Only 42 patients received maintenance IL-2. The average received maintenance dose of IL-2 was also
approximately 30% of planned. Most dose reductions were due to toxicity or patient refusal. Three-year
survival and progression-free survival for all registered patients were 43% (95% confidence interval [CI],
33%-53%) and 31% (95% CI, 21%-41%), respectively. For the 60 patients undergoing transplantation, they
were 59% (95% CI, 46%-72%) and 44% (95% CI, 31%-57%), respectively. There was no relation between the
dose of IL-2 received and outcome. Survival and disease-free survival of the study group were similar to those
of a previous study cohort that received unmanipulated stem cells and no systemic IL-2. Administration of
IL-2–incubated peripheral blood stem cells and intensive posttransplantation IL-2 was associated with con-
siderable but rapidly reversible toxicity. No effect on long-term outcome was observed.
© 2004 American Society for Blood and Marrow Transplantation
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INTRODUCTION
High-dose chemotherapy with autologous trans-
lantation is the treatment of choice for patients with
ecurrent lymphoma, but it is effective in only a mi-
ority of patients because of a high incidence of dis-
ase recurrence [1-3]. Lymphomas are also sensitive to
mmunotherapy, as indicated by their responses to
nterferon [4-6] and in particular to interleukin (IL)–2
7,8]. Although IL-2 has activity as a single agent, it86oes not induce durable responses when used in pa-
ients with established disease, and it has long been
hought that the optimal use for it might be in the
etting of minimal residual disease, as is commonly
chieved after high-dose chemotherapy [9].
We have studied in vitro incubation of stem cells
ith IL-2 followed by immediate posttransplantation
dministration of systemic IL-2. A potential advantage
f this approach is that the in vitro incubation with
L-2 might have a “purging” effect; ie, it might lead to
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Autologous Transplantation in Relapsed or Refractory NHL
Bhe eradication of occult lymphoma cells contained in
he stem cell graft that otherwise might contribute to
isease recurrence. Indeed, murine experiments indi-
ate that the administration of IL-2–incubated stem
ells, followed by posttransplantation IL-2, resulted in
powerful antileukemic effect [9,10]. We initially
emonstrated the feasibility of this approach in pa-
ients with leukemia and lymphoma [11]. Here we
resent the results of a phase II study in patients with
ecurrent lymphoma.
ATIENTS AND METHODS
ligibility Criteria
Patients between the ages of 15 and 65 years with
elapsed or refractory intermediate-grade, low-grade,
r immunoblastic lymphoma were eligible. Those
ith mantle-cell lymphoma and transformed lym-
homa were also eligible. Documentation of histology
t the time of relapse by biopsy or ﬁne-needle aspira-
ion cytology was recommended but not required.
he laboratory requirements were as follows: absolute
ranulocyte count 1.5  109/L, platelet count
100  109/L, bilirubin 1.2 mg/dL, serum creati-
ine 2.0 mg/dL (unless due to disease), human im-
unodeﬁciency virus antibody negative, and no evi-
ence of active hepatitis or cirrhosis.
The organ function requirements were as follows:
erformance status of 2, no symptomatic heart dis-
ase, diffusion capacity of the lung for carbon mon-
xide50% of predicted, forced expiratory volume in
second 50% of predicted, no active connective
issue disorder, no history of seizures, and no pleural
ffusion, pericardial effusion, or ascites, unless caused
y lymphoma. Patients were excluded if they had
vidence of central nervous system involvement at
elapse.
The protocol was approved by the institutional
eview boards at the M.D. Anderson Cancer Center
nd at the University of Illinois at Chicago, and vol-
ntary written, informed consent was obtained from
ach patient before beginning the protocol treatment.
reatment
Salvage chemotherapy consisted of 1 to 3 cycles of
fosfamide and etoposide [2] (Table 1). Upon recovery
rom the ﬁrst or second treatment cycle, stem cell
pheresis was performed. Patients underwent frequent
e-staging between cycles, and when a maximal re-
ponse (complete response [CR], stable partial re-
ponse [PR], and in some cases a minor response) was
chieved, they proceeded to transplantation. Ifos-
amide/etoposide consisted of the following: before
hemotherapy patients received mesna 2 g/m2 intra-
enously (IV) over 2 hours. This was followed by
2 2fosfamide 3.3 g/m /d mixed with mesna 2.66 g/m /d d
B&MTn continuous infusion for 3 consecutive days (total
ose of ifosfamide 10 g/m2). After the ifosfamide was
ompleted, patients continued to receive mesna 2
/m2 by continuous infusion for 12 hours. Patients
lso received etoposide 150 mg/m2 IV over 2 hours
very 12 hours for 3 consecutive days (the total dose of
toposide was 900 mg/m2).
After every course of chemotherapy, patients re-
eived subcutaneous granulocyte colony-stimulating
actor 5 g/kg daily. This dose was doubled to 5
g/kg twice daily after the course of ifosfamide/eto-
oside that was used for stem cell mobilization. After
reatment with ifosfamide/etoposide, patients received
ral quinolones, ﬂuconazole, and acyclovir until re-
overy of neutrophil counts. Packed red blood cells
ere administered for hemoglobin 8 g/dL, and
latelets were administered for a platelet count20
09/L. All blood products were ﬁltered and irradiated.
he target cell dose for stem cell mobilization was 8
06 CD34 cells per kilogram. At least 3  106 CD34
ells per kilogram were to be kept as a backup, and the
est were to be used for in vitro incubation.
onditioning Regimens
The conditioning regimen for patients with inter-
ediate-grade, transformed, or immunoblastic lym-
homa was BEAM chemotherapy. BEAM consisted of
armustine 300 mg/m2 IV over 1 hour on day 6;
toposide 200 mg/m2 IV over 6 hours every 12 hours
n days 5, 4, 3, and 2 (total of 8 doses); cyt-
rabine 200 mg/m2 IV over 30 minutes every 12 hours
n days 5, 4, 3, and 2 (total of 8 doses); and
elphalan 140 mg/m2 IV on day 1. Patients re-
eived an infusion of peripheral blood stem cells on
able 1. Treatment Scheme
nduction: 1-3 courses Ifosfamide 3.3 gr/m2 3 days
Etoposide 150 mg/m2 q 12 hrs
 6 doses
Mesna
G-CSF
tem cell mobilization >8  106 CD34 cells/kg collected upon
recovery from ifosfamide/etoposide
onditioning BEAM chemotherapy
BSC >5 106 CD34 cells/kg IL2 incubated
24 hours.
Concentration 3106 cells/ml, IL2
6000 IU/ml
ost-transplant
immunotherapy
IL2 1 MU/m2 day (SQ or IV) daily day
1-21
GM-CSF 250 mcg/m2 day1-recovery
aintenance IL2 IL2 4 MU/m2 day 1-5 and day 8-12,
2 weeks/month  4 consecutive
months
CSF indicates granulocyte colony-stimulating factor; PBSC, pe-
ripheral blood stem cell; SQ, subcutaneously; GM-CSF, gran-
ulocyte-macrophage colony-stimulating factor.ay 0.
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3Patients with low-grade lymphoma were prefera-
ly given a total body irradiation (TBI)–containing
egimen consisting of etoposide 1500 mg/m2 IV on
ay 8, cyclophosphamide 60 mg/kg IV over 2 hours
n days 7 and 6, and TBI. TBI 12 Gy was admin-
stered in 4 daily fractions of 3 Gy on days 4, 3,
2, and 1 with lung shielding.
hawing and Activation of Peripheral Blood
rogenitor Cells on Day 1
Each bag of cryopreserved peripheral blood pro-
enitor cells (PBPC) was thawed rapidly in a 40°C
ater bath. Cell count, viability, Gram stain, culture,
nd assays for colony-forming units were performed
n a small aliquot of the thawed product. The culture
ags for incubation of PBPC with IL-2 were prepared
y adding each 50-mL aliquot of PBPC from the
hawed cryopreservation bags to a 1-L incubation bag
ontaining RPMI 1640 medium with the following
dditives: l-glutamine 2 mmol/L, -mercaptoethanol
 105 mol/L, gentamicin 0.05 mg/mL, deoxyribo-
uclease 0.2 mg/mL, heparin 50 U/mL, IL-2 6000
U/mL, and 10% autologous plasma that had been
ollected and frozen at the time of stem cell harvest.
he cell concentration in this incubation mixture was
 106/mL.
After 18 to 24 hours of incubation in a 5% CO2
ncubator, the contents of each bag were harvested
nd washed in the cell separator with the RPMI 1640
edium containing 5% autologous plasma.
eripheral Blood Stem Cell Infusion
The product was resuspended in approximately
50 mL of autologous plasma and infused over
pproximately 1 hour while vital signs were closely
onitored. Patients were premedicated with diphen-
ydramine 25 mL IV, meperidine 50 mg IV, and
cetaminophen 650 to 1000 mg by mouth. Cortico-
teroids were avoided. A small portion of the cell
uspension was used for the Gram stain and endotoxin
ssay to be performed immediately before reinfusion.
ranulocyte-Macrophage Colony-Stimulating
actor
Granulocyte-macrophage colony-stimulating fac-
or 250 g/m2 (subcutaneously or IV daily) was
tarted on day 1 after transplantation and was contin-
ed until the absolute neutrophil count reached 1 
09/L for 3 consecutive days.
L-2 Therapy
Posttransplantation IL-2. IL-2 was started 24 hours
fter the infusion of autologous activated stem cells to
llow for the potential toxicities of the infusion to
esolve. The initial IL-2 dose was 1 mIU/m2/d by
ontinuous IV infusion, and this infusion was to be c
88ontinued for 21 days. Patients discharged before day
1 could be switched to an equivalent subcutaneous
ose.
Maintenance IL-2. A 1-week rest period was pro-
ided after completion of the initial low-dose IL-2
nfusion. Thereafter, the IL-2 dose was escalated to 4
IU/m2 subcutaneously twice daily for 5 days fol-
owed by a 48-hour rest interval and another 5-day
reatment. This 12-day treatment cycle was repeated
pproximately every month for a total of 4 cycles.
IL-2 Toxicities and Dose Adjustment. Strict guide-
ines for the management of IL-2 toxicities and dose
djustments during the postinfusion (hematologic re-
onstitution) period could not be provided, because
any of the clinical and laboratory complications dur-
ng this time were similar to the toxicities of IL-2 in
he nontransplant setting. A general guideline for the
ithholding of therapy and potential resumption at
ose decrements of 50% was based on the judgment of
he treating physician and of the principal investigator
s to the contribution of IL-2 to serious toxicities.
The National Cancer Institute common toxicity
riteria were used for the assessment of IL-2 toxicities,
s deﬁned previously. IL-2 was to be withheld for any
erious organ toxicity that was not easily managed
ith standard supportive care such as antiemetics,
ntipyretics, and IV ﬂuids or for any medical compli-
ation of the transplantation to which IL-2 was judged
o be contributing. If such toxicity resolved within 72
ours and was not considered life-threatening or at-
ributable to IL-2, then IL-2 could be resumed at 50%
f the original dose. Recurrence of similar toxicities
as an indication for discontinuation of IL-2.
osttransplantation Evaluation and Response
riteria
Response to therapy was evaluated after every
reatment course; approximately 3 months, 6 months,
nd 1 year after transplantation; and annually there-
fter. Evaluation consisted of physical examination;
lood counts; chest radiograph; computed tomogra-
hy of the chest, abdomen, and pelvis; and marrow
spirate and biopsy for those with a history of bone
arrow involvement. Gallium scanning, although
outinely used, was not considered in the formal as-
essment of response. Additional tests—such as immu-
ophenotyping of the blood and bone marrow, lymph
ode aspiration, or biopsy—were performed when
linically indicated. CR was deﬁned as the disappear-
nce of all clinical and radiologic evidence of active
umor. PR was deﬁned as a50% decrease in the sum
f the products of all measured lesions. Stable disease
as deﬁned as no change in the size of the measurable
esions or a response that was less than a partial re-
ission and no progression for a minimum of 8 weeks.
here could be no appearance of new lesions for this
ategory.
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Autologous Transplantation in Relapsed or Refractory NHL
Btatistical Design and Analysis
This was a single-arm phase II study. Sample size
as calculated with the method of Dixon and Simon
12]. We estimated that an accrual of approximately
2 patients would provide sufﬁcient power to reject
he null hypothesis of 30% long-term disease-free
urvival observed in a historical cohort. Primary out-
omes analyzed were progression-free and overall sur-
ival. Probabilities of primary outcomes were calcu-
ated with the Kaplan-Meier product-limit estimate
13] and expressed as probabilities with a 95% conﬁ-
ence interval (CI).
Because our main interest was in identifying the
ole of IL-2 incubation and posttransplantation IL-2
n the outcome of transplantation, the analysis was
estricted to the subset of patients who, after a re-
ponse to salvage therapy, underwent transplantation.
n this cohort, we evaluated the importance of the
ollowing covariates: disease histology, disease re-
ponse (CR versus PR versus minimal response), num-
er of prior treatments, dose of IL-2 received after
ransplantation, and percentage of planned IL-2 re-
eived during maintenance therapy. Because of the
imited patient number, no multivariate analysis was
ttempted. Univariate comparisons used the log-rank
est [14]. To evaluate the effect of IL-2 incubation on
utcome, the data were combined with those from a
revious study with similar eligibility criteria, salvage
herapy, and conditioning regimen. In this historical
ontrol group, patients did not receive posttransplan-
ation IL-2 or IL-2–incubated stem cells [2].
ESULTS
atient Characteristics
Ninety-ﬁve patients were enrolled between April
997 and July 2000. Eighty were enrolled at the M.D.
nderson Cancer Center and 15 at the University of
llinois at Chicago. Two patients were ineligible be-
ause of erroneous diagnosis (1 Hodgkin disease and 1
urkitt lymphoma), 1 because of a history of chronic
yelogenous leukemia, and 2 because of thrombocy-
openia before enrollment. Six were not evaluable
ecause they received nonprotocol treatment. Among
he 84 evaluable patients, there were 44 men and 40
omen, with a median age of 47 years (range, 18-65
ears). Fifty-seven patients had diffuse large B-cell
ymphoma, 9 had primary mediastinal B-cell lym-
homa, and 8 had follicular lymphomas. Four patients
ad mantle-cell lymphoma. Four patients had anaplas-
ic large-cell lymphoma, and 3 had other types of
eripheral T-cell lymphoma. All patients had either
ecurrent or refractory disease. Ninety-four percent
ad a good performance status, but one third had
ncreased serum lactate dehydrogenase. Twenty per-
ent had primary refractory disease, and the rest had l
B&MTither ﬁrst or second recurrence. Forty-three percent
f the patients were enrolled at the time of documen-
ation of recurrence, and the ifosfamide/etoposide
egimen was used as the salvage regimen. They were
herefore “untested” recurrences. The remainder of
he patients were enrolled after receiving some other
orm of chemotherapy to which they were sensitive
44%) or refractory (12%). As a result, 11% of the
atients were already in complete remission at enroll-
ent.
fosfamide/Etoposide
As previously reported, the ifosfamide/etoposide
egimen is a highly myelosuppressive, but effective,
egimen, and only 18 (22%) of the 84 patients did not
espond [2]. Six patients with responsive disease did
ot proceed to transplantation, in four cases because
f prolonged myelosuppression and a resulting inabil-
ty to collect stem cells. One patient had severe cardiac
omplications that precluded transplantation, and 1
atient refused to proceed with transplantation.
utologous Transplantation and
osttransplantation IL-2
Sixty patients proceeded to transplantation. Fifty-
even received conditioning with BEAM, and 3 re-
eived conditioning with cyclophosphamide/etopo-
ide TBI (Table 2). Stem cells incubated with IL-2
ere infused on day 0 in 56 patients. Four patients
eceived nonincubated stem cells because the col-
able 2. Characteristics of Study Patients Undergoing
ransplantation versus Patients in the Prior Study Group
ndergoing Transplantation
Variable
Study
Group
Historical
Control
o. patients undergoing
transplantation 60 35
edian age, y (range) 50 (25-65) 49 (27-62)
henotype
B cell 77 (92%) 29 (83%)
T cell 5 (6%) 5 (14%)
Unknown 2 (2%) 1 (3%)
istology
Follicular lymphoma 7 (12%) 5 (14%)
Diffuse large B cell 44 (73%) 26 (74%)
Mantle-cell lymphoma 3 (5%)
Anaplastic large-cell
lymphoma 4 (7%) 3 (8%)
Other peripheral T cell 2 (4%)
Lymphomatoid
granulomatosis 1 (3%)
esponse status at
transplantation
CR 27 (45%) 16 (46%)
PR 24 (40%) 17 (48%)
Minor response 9 (15%) 2 (6%)ected stem cell dose was insufﬁcient. As previously
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3eported [11] and as summarized in Table 3, fever and
hills were frequently associated with the infusion of
hese stem cells. Mild, reversible hypotension also
ccurred in 17% of patients. Reversible hypoxia oc-
urred in 10%. Arrhythmias occurred in 3 patients,
nd temporary transfer to the intensive care unit was
ecessary in 2. The cells had been washed to remove
L-2 and dimethyl sulfoxide before reinfusion. The
oxicities are therefore attributable to direct effects of
he incubated cells. All toxicities were mild: no grade
toxicities occurred.
Posttransplantation IL-2 was started in all pa-
ients, but the dose often had to be reduced because of
ubjective intolerance and fever. Received doses are
ummarized in Table 4. Only a third of the patients
eceived the full planned dose of IL-2, and most re-
eived between 30% and 50% of the planned dose. By
omparison, the average received dose in our phase I
tudy was 74%. Hypotension, chest pain, and renal
ailure occurred in 1 patient each. There were no
reatment-related deaths in the ﬁrst month after trans-
lantation.
aintenance IL-2
Forty-two patients started the ﬁrst cycle of main-
enance IL-2. Twenty-eight patients received all 4
lanned cycles, 5 received 3 cycles, 4 received 2 cycles,
nd 5 received only 1 cycle. Dose reductions were also
ommon, and only 4 patients received all of the
lanned maintenance treatment. The median received
ose was approximately 30% of planned, consistent
ith observations in the phase I study. Reasons for
ose reduction or discontinuation were progressive
isease in 3 patients, sepsis in 1 patient, toxicity in 35
atients, and refusal in 11 patients.
A total of 140 cycles of maintenance IL-2 were
able 3. Grade I and II Toxicities Related to Infusion
f IL-2–Incubated Stem Cells
Toxicity %
ever 18%
hills 27%
ypotension 17%
rrhythmia 6%
ypoxia 10%
ransfer to intensive care unit 4%
able 4. Cumulative Dose of IL-2 Received in the First 21 Days
as a Percentage of the Planned Dose)
Planned Dose % % Received
10%-30% 5%
30%-50% 55%
50%-90% 20%
100% 30%
a
90dministered, but toxicity information was available
or only 121 of these cycles and is summarized in
able 5. Fever was extremely common. Mild GI tox-
city (nausea, diarrhea, and vomiting) was common, as
ere headaches and lethargy. Usually such toxicities
ere rapidly reversible with dose reduction or discon-
inuation. There was 1 documented seizure, 1 case of
ulmonary emboli, and 1 case of severe liver and
evere gastrointestinal toxicity. One case of cryoﬁbri-
ogenemia and skin necrosis has been separately re-
orted [15]. Gram-negative sepsis occurred during
% of the maintenance courses and was fatal in 1 case.
urvival and Disease-Free Survival: Effect of IL-2
reatment and IL-2 Incubation
With a median follow-up of 40 months (range,
3-55 months), the estimated 3-year survival and pro-
ression-free survival are 43% (95% CI, 33%-53%)
nd 31% (95% CI, 21%-41%), respectively, for the
ntire study population (ie, all 84 eligible patients).
his is similar to what we observed in previous studies
2,16].
In the subgroup of 60 patients who proceeded to
ransplantation, there was only 1 treatment-related
eath, which was due to sepsis after a course of main-
enance IL-2. Estimated survival and disease-free sur-
ival in patients undergoing transplantation were 59%
95% CI, 46%-72%) and 44% (95% CI, 31%-57%),
espectively. We could not detect a correlation be-
ween days of posttransplantation IL-2, cumulative
ose of posttransplantation IL-2, or the cumulative
ercentage of maintenance IL-2 and progression-free
urvival (Figures 1 and 2).
In an additional analysis, we attempted to assess
he effect of IL-2 incubation of stem cells on long-
erm outcome. For that purpose, we combined the
ata on our study patients with those of a previous
tudy of an ifosfamide/etoposide regimen followed by
able 5. Toxicities and Infections Occurring during Administration
f Maintenance IL-2 (121 Episodes)
Variable
NCI Toxicity Grade
1 2 3 4
ausea/vomiting 35 (29%) 4 (3%) 0
I 17 (14%) 2 (2%) 1 (1%)
iver 1 (1%) 0 1 (1%)
ulmonary 6 (5%) 2 (2%) 1 (1%)
enal 2 (2%) 6 (5%)
NS 22 (19%) 12 (10%) 1 (1%)
kin 9 (7%) 6 (5%)
nfections
Gram-negative sepsis 6 (5%)
Gram-positive sepsis 2 (2%)
CI indicates National Cancer Institute; CNS, central nervous
system.utologous stem cell transplantation with unmanipu-
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Bated stem cells [2]. Forty-ﬁve patients participated in
hat study, of whom 35 proceeded to transplantation.
ombining the 2 groups resulted in a study cohort of
5 patients undergoing transplantation. Ninety-one of
hese received BEAM conditioning, and 56 received
L-2–incubated stem cells. The characteristics of both
tudy groups were similar, as summarized in Table 2.
here were no signiﬁcant differences in progression-
ree survival between those receiving IL-2–incubated
tem cells and those receiving unmanipulated stem
ells (Figure 3).
ISCUSSION
Dose intensiﬁcation with hematopoietic stem cell
escue after conventional salvage therapy is the stan-
ard of care for patients with recurrent lymphoma and
s particularly effective in patients whose lymphoma
as responded to salvage chemotherapy [1,17]. Recur-
ences after autologous transplantation account for a
igure 1. Progression-free survival after transplantation for pa-
ients who received IL-2–incubated peripheral blood stem cells.
he effect of cumulative doses of posttransplantation IL-2 received
s shown.
igure 2. Progression-free survival after transplantation for pa-
ients who received IL-2–incubated peripheral blood stem cells.the effect of maintenance doses of IL-2 is shown.
B&MTarge proportion of the treatment failures and may be
xplained by 2 mechanisms: (1) failure of the high-
ose conditioning regimen to eradicate the underlying
isease and (2) recurrence derived from occult lym-
homa cells contained in the stem cell graft. The
trategy pursued in our trial was meant to address
hese 2 issues simultaneously. IL-2 is a potent stimu-
ator and survival factor for T cells and natural killer
NK) cells and probably derives its antitumor efﬁcacy
rom its immunostimulatory effects [7,8,18-20]. It
ay have its major effect in situations of minimal
esidual disease achieved after high-dose chemother-
py. Furthermore, the immunologic reconstitution af-
er autologous or allogeneic stem cell transplantation
s characterized by an early recovery of NK cells
ollowed by somewhat delayed T-cell recovery, with a
reponderance of cytotoxic T cells [21-24]. This early
osttransplantation environment may be particularly
uitable for the effects of IL-2 [25]. However, IL-2 has
onsiderable systemic and potential hematopoietic
oxicity [26], which may be exacerbated in the weeks
fter high-dose chemotherapy [27]; therefore, in many
rials, its administration has been delayed until after
ematopoietic recovery. Studies of posttransplanta-
ion IL-2 have been conducted in both the allogeneic
nd autologous transplant settings. Varying doses and
chedules have been evaluated [9,27-37]. Biological
ctivity is well documented, but the only group to
eport a substantial beneﬁt from posttransplantation
L-2 was the Hadassah group. They administered
igh doses of IL-2 in combination with interferon
tarting 2 to 10 months after transplantation for ag-
ressive lymphoma and Hodgkin disease, and they
eported excellent tolerance and a survival beneﬁt
hen compared with historical controls [38]. The
reatment was delayed for up to 10 months after trans-
lantation in this study and therefore was almost cer-
igure 3. Progression-free survival after transplantation. The effect
f incubation of peripheral blood stem cells (PBSC) with IL-2 and
dministration of posttransplantation IL-2 is shown.ainly limited to a rather favorable-risk group of pa-
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3ients. In addition, IL-2 was combined with
nterferon, and it is conceivable that most of the ac-
ivity resulted from the interferon, which previously
as been shown to improve survival in lymphoma
5,39]. The use of posttransplantation IL-2 was also
valuated in 2 randomized studies. The Southwest
ncology Group is conducting a randomized study of
osttransplantation IL-2 in lymphoma that is nearing
ompletion. A French cooperative group study of
osttransplantation IL-2 in acute lymphatic leukemia
n ﬁrst remission showed no beneﬁt [40].
A slightly different approach consists of stimulat-
ng NK cell precursors in bone marrow or stem cells
n vitro with IL-2 in an attempt to increase antitumor
ctivity and to purge the graft of contaminating cells
41-43]. In vitro stimulated lymphokine-activated
iller cells lack hematopoietic toxicity but seem to be
ble to selectively deplete malignant cells [44-49]. The
easibility and in vitro efﬁcacy of this technology were
alidated by several groups [48,50-55]. We tested this
n our initial phase I study of 32 patients with hema-
ologic malignancies, and we found reasonable toler-
nce and rapid hematopoietic reconstitution after
ransplantation [11]. We were able to administer an
verage of 70% of a planned dose of 1  106 IU/m2/d
f IL-2 in the ﬁrst 21 days after transplantation, as
ell as 30% of a planned maintenance dose of 6 106
U/m2/d for 10 days every month for 4 months. The
nitial results in lymphoma patients were particularly
ncouraging, with 9 of 19 patients with advanced
efractory disease surviving disease free [56].
The patient selection criteria, chemotherapy in-
uction, and transplant conditioning regimen of the
ubsequent phase II study were modeled after a prior
tudy of salvage chemotherapy at M.D. Anderson [2].
n identical ifosfamide-based induction was used, as
as a consolidation with BEAM chemotherapy. It was
herefore anticipated that patients participating in the
rior study would serve as historical controls. Re-
ponse rates to salvage chemotherapy and tolerance to
osttransplantation IL-2 were similar to what we had
reviously observed, although the ability to administer
he posttransplantation IL-2 was slightly reduced,
erhaps because of the higher median age of patients
n the phase II study. Considerable symptomatology
as attributed to IL-2 and consisted mainly of fever,
eneral malaise, and skin rashes. Severe side effects
lso occasionally occurred after infusion of the IL-2–
ncubated stem cells, similar to what others have ob-
erved [37]. Life-threatening side effects related to cell
nfusion or IL-2 were rare. The IL-2–related symp-
oms led, however, to frequent dose reductions or
ven patient refusal to continue the treatment.
Disappointingly, the long-term outcome of our
atients was not different from that observed in pre-
ious studies, and we failed to detect an effect of the
ose of IL-2 received during maintenance treatment r
92r immediately after transplantation on the outcome
f the transplantation. We attempted to analyze the
ffect of the complete treatment strategy (ie, the se-
uence of stem cell incubation with IL-2 followed by
n vivo IL-2) by pooling the data with outcome data
rom our historical controls and also failed to detect an
ffect on relapse rates. Our results are reminiscent of
he report by Burns et al. [37], who used lymphocytes
hat were obtained by apheresis, incubated in vitro
ith IL-2, and then reinfused to autologous transplant
atients with either metastatic breast carcinoma or
ymphoma. In a second cohort of patients, they in-
used bolus doses of IL-2 as an alternative to cell
herapy. Despite marked biologic effects, they did not
bserve any clinical beneﬁt from either of these ap-
roaches.
The failure of immunotherapy with IL-2 to affect
ecurrence rates in these studies, despite biological
ctivity, may be explained in a number of ways. It
ould be due to an inappropriate dose or schedule of
dministration of posttransplantation IL-2. One arti-
le suggests that both low and high doses of IL-2 are
ssociated with a lack of activation [25]. Weisdorf et
l. [27] used a similar dose of IL-2 after transplanta-
ion and found serum levels of 5 to 20 U/mL, which
as sufﬁcient only to stimulate the very-high-afﬁnity
eceptors [57]. The planned regimen of IL-2 used in
ur trial was, however, more intense than in most
ther trials and turned out not to be practical in many
atients; dose reductions were often required, and
nless novel methods are identiﬁed to reduce the
oxicity of IL-2, it is unlikely that further dose esca-
ation will be possible. In this regard, the recent de-
cription of a selective inhibitor of IL-2 toxicity is of
articular interest [58,59]. It is also possible that we
ailed to detect a true effect (type II error), a risk that
s somewhat increased by the use of a historical con-
rol group, which may have failed to take into account
n unrecognized imbalance in prognostic features.
till, if this were the case, any true effect of our
ntervention on recurrence rates is likely to have been
mall.
The failure of our trial underscores the need for
nnovative approaches to improve outcome after au-
ologous transplantation. IL-2, because of its biologic
ffects, continues to have considerable interest and
as, for example, been combined with rituximab to
ncrease antibody-dependent cellular cytotoxicity [60].
combination of IL-2, rituximab, and granulocyte-
acrophage colony-stimulating factor given as post-
ransplantation therapy is currently being tested at our
nstitution.
In summary, this is, to our knowledge, the largest
rospective phase II trial of posttransplantation IL-2
nd IL-2–incubated stem cells for patients with recur-
ent lymphoma. Toxicity was considerable but usually
apidly reversible. No effect of this strategy on long-
t
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Berm outcome was observed. We conclude that stem
ell transplantation with IL-2–incubated peripheral
lood stem cells and posttransplantation IL-2 given in
his fashion is unlikely to result in major beneﬁts for
atients with recurrent lymphoma.
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